Erol Demir

Koç Üniversitesi TIREX ve KUIS AI ile geliştirdiğimiz Çapraz Böbrek Nakli Projesi'ni, T.C. Sağlık Bakanlığı Organ Nakli Daire Başkanı Prof. Erkan Ölçücüoğlu, Sağlık Hizmetleri Genel Müdürlüğü’nden Ömer Bal ve Sağlık Bakanlığı heyetine takdim ettik. Destekleri için teşekkür ederiz

🧵 1/9 As Nephrology Dialysis Transplantation @NDTsocial celebrates 40 years 🎉, a new editorial ✨ highlights how biological sex shapes CV benefits of exercise in CKD. @VanAmaryllis @olgabalafa @anagarcp #WERA Read the full article at 🔗academic.oup.com/ndt/advance-ar… Read the thread for a sneak peek 👇👇 👇

🤝 The Developing Education Science and Care for Renal Transplantation in European States Working Group (DESCaRTES) gathered on March 19–20, 2026, for its Annual Meeting to discuss ongoing and future research projects aimed at improving care for patients through education and research, while fostering networking among clinicians and experts in kidney transplant. 📸 Here's a glimpse of the meeting!

Koç Üniversitesi TIREX ve KUIS AI ile geliştirdiğimiz Çapraz Böbrek Nakli Eşleştirme Yazılımı ve Projesi'ni, Sağlık Bakanımız Sayın Prof. Dr. Kemal Memişoğlu ve Bakan Yardımcımız Sayın Prof. Dr. Nurullah Okumuş'a takdim ettik. Değerli ilgi ve destekleri için teşekkür ederiz.

In our recent Transplant International paper, in which we analyzed more than 20,000 kidney transplantations from the CTS Study in Heidelberg (10.3389/ti.2025.15207), we report that a low tacrolimus CDR is a strong predictor of inferior outcomes.

Kronik böbrek yetmezliği ve böbrek nakli hakkında kısa bir bilgilendirme videosu. Hastalarımıza faydalı olması umuduyla 🌿 youtu.be/GF6L7ITY0lw #Nefroloji #KBH #BöbrekNakli @yeditepeunihst @KanalD

-Kronik böbrek yetmezliği nedir ve neden oluşur? -Kronik böbrek yetmezliğinin erken belirtileri var mı? Hangi şikayetler dikkate alınmalı? -Diyabet ve hipertansiyon varlığı kronik böbrek yetmezliği riskini nasıl artırır mı? Nefroloji Uzmanı Doç. Dr. Erol Demir Kanal D @konustukcatv programında, ‘’Kronik Böbrek Yetmezliği’’ ve Organ Nakline Götüren Süreçler hakkında merak edilen soruları yanıtlıyor. 📌 23.11.2025 Pazar günü gerçekleşecek programı sakın kaçırmayın. #YeditepeÜniversitesiHastaneleri #BöbrekYetmezliği #BöbrekSağlığı #İçHastalıkları #Nefroloji

Beautiful diagram depicting all aspects of ANCA-Associated Vasculitis (AAV) 🩸 It perfectly shows how: 🔹 PR3-ANCA → GPA — airway & ENT disease, granulomas, relapsing course 🔹 MPO-ANCA → MPA — pulmonary–renal, ILD, neuropathy, higher mortality 🔹 EGPA — eosinophilia, asthma, nasal polyps (often ANCA-negative) 🧭 PR3 = relapsing ⚰️ MPO = severe 🌪️ EGPA = eosinophilic overlap AAV isn’t three boxes — it’s one evolving spectrum. #RheumTwitter #MedTwitter #Vasculitis @DrAkhilX @IhabFathiSulima @CelestinoGutirr

International consensus on post-transplantation diabetes mellitus doi.org/10.1093/ndt/gf…

Now out in @JASN_News @StefanieSteige6 @PRomagnani How to Cure Autoimmune GN and podocytopathies 🧐 All autoimmune kidney diseases, no matter what histotype or clinical presentation, benefit from a clone-directed immunotherapy. ▶️journals.lww.com/jasn/abstract/…

An update to the Obesity Canada Pharmacotherapy Clinical Practice Guidelines, published today. An emphasis on each medication's potential to impact individual obesity-related complications ttps://www.cmaj.ca/content/197/27/E797

❤️‍🩹Heart Failure drugs use according to CKD stage ajkd.org/action/showPdf… @AJKDonline

🫘GLP-1 RA in Metabolic Disease 😬⏬Obesity related complications doi.org/10.1093/ndt/gf… @NDTsocial @hjanders_hans

The oral GLP !! Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | ⁦@NEJM⁩ nejm.org/doi/full/10.10…

Alport spectrum

#ADA2025: RGT-075 – Oral GLP-1 RA Enters the Ring 💊 Small molecule shows weight loss and BP reduction at 12 weeks 🧪 Phase 2a (n=73; BMI ≥30 or ≥27 + comorbidity) 🧍 Mean WL at 12 wks: −5.4% (RGT-075) vs −0.45% (pbo) – No plateau at 12w 📉 BP ↓:  • Systolic −10.8 mmHg  • Diastolic −4.9 mmHg 🤢 AEs: nausea (40%), vomiting (24%) – mostly mild/mod 🛑 Discontinuation: 4% (same as pbo)✅ 👉Oral, non-peptide GLP-1RA with robust metabolic signal 📌 Poster 785-P #Obesity #GLP1 #OralGLP1 #RGT075

#ADA2025: Eloralintide Enters the Chat 💬 New long-acting amylin receptor agonist (Elora, QW 💉) shows early promise for obesity 📊 Phase 1 (n=100, BMI 27–43) • Mean weight ↓ at 12wks: −2.6% to −11.3% • t½ ~14–16 days • PK exposure dose-proportional 🤢 GI AEs: • Diarrhoea 10% • Nausea 8% • Vomiting 4% 🧠 Other AEs: ↓appetite (19%), headache (12%), fatigue (11%) 🛑 1 SAE (unrelated), 0 deaths 🔁 QW Elora well tolerated. Phase 2 next. Another amylin angle after Cagri? 🔗 ADA 882-P –2025 #Obesity #Amylin #Eloralintide #GLP1adjacent #ADA2025

Obesity accelerates cardiovascular ageing This review evaluates the intricate interplay between obesity and ageing from molecular mechanisms to whole organ function within the cardiovascular system academic.oup.com/eurheartj/arti…

Aspirin for primary prevention: new scores for old questions? bit.ly/4czAWtz

🫘Phosphate Binders doi.org/10.1093/ckj/sf… @CKJsocial